Hansa Biopharma

Virtual Investor Event

Autoimmune Deep Dive
Guillain-Barré Syndrome

Join Hansa Biopharma for an investor event featuring two KOLs discussing unmet need and current treatment landscape for Guillain-Barré syndrome (GBS).

June 16, 14:00 CEST/8:00 AM ET

Register and attend
CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical to present IdeS at the World Orphan Drug Congress USA, April 24 in Washington D.C.

10 Apr 2014, 13:00
The presentation focusing on Hansa Medical’s lead drug-candidate IdeS’ capacity for desensitization prior to kidney transplantation is scheduled for 3:15 pm on April 24.

The World Orphan Drug Congress USA will be held on April 23-25 at the Grand Hyatt Washington, Washington D.C. For more information about the event please visit: www.terrapinn.com/2014/world-orphan-drug-congress-usa.

The company presentation’s emphasize will be on its lead drug-candidate IdeS, IdeS’ recent clinical Phase I results and IdeS’ forthcoming Phase II studies in 2014.

Files

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77
E-mail: [email protected]
www.hansamedical.com

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.